Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 known ✓ | P14416 | 2/20 | 0.55 |
| ▸ | DRD3 known ✓ | P35462 | 2/20 | 0.55 |
| ▸ | MAOB known ✓ | P27338 | 1/20 | 0.52 |
| ▸ | HTR2A known ✓ | P28223 | 1/20 | 0.50 |
| ▸ | HTR2C known ✓ | P28335 | 1/20 | 0.50 |
| ▸ | HTR2B known ✓ | P41595 | 1/20 | 0.50 |
| ▸ | ADRA2A known ✓ | P08913 | 1/20 | 0.48 |
| ▸ | ADRA2B known ✓ | P18089 | 1/20 | 0.48 |
| ▸ | ADRA2C known ✓ | P18825 | 1/20 | 0.48 |
| ▸ | ASIC3 | Q9UHC3 | 2/20 | 0.96 |
| ▸ | PNMT | P11086 | 5/20 | 0.81 |
| ▸ | CD44 | P16070 | 1/20 | 0.52 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.44 |
| ▸ | PARP11 | Q9NR21 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL505055 | 0.98 | ASIC3 (1.00) | ASIC3PNMTDRD2DRD3CD44 | |
| Hydrochloric Acid SCHEMBL29528420 | 0.92 | PNMT (0.96) | ASIC3PNMTDRD2DRD3CD44 | |
| Hydrochloric Acid SCHEMBL1266299 | 0.92 | PNMT (0.96) | ASIC3PNMTDRD2DRD3CD44 | |
| SCHEMBL29473102 | 0.90 | PNMT (1.00) | ASIC3PNMTDRD2DRD3CD44 | |
| SCHEMBL552932 | 0.90 | PNMT (1.00) | ASIC3PNMTDRD2DRD3CD44 | |
| Hydrochloric Acid SCHEMBL21753254 | 0.89 | ASIC3 (0.76) | ASIC3PNMTDRD2DRD3CD44 | |
| Hydrochloric Acid SCHEMBL21753269 | 0.88 | PNMT (0.74) | ASIC3PNMTDRD2HTR2AHTR2C | |
| SCHEMBL1264714 | 0.86 | ASIC3 (0.79) | ASIC3PNMTDRD2DRD3CD44 | |
| SCHEMBL29758914 | 0.86 | ASIC3 (0.79) | ASIC3PNMTDRD2DRD3CD44 | |
| SCHEMBL1264341 | 0.85 | PNMT (0.77) | ASIC3PNMTDRD2HTR2AHTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 77 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4423068-B1 | RXFP1 AGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2025-12-03 | — | — | EP | disclosed |
| CN-115894363-B | Synthesis process of 6-bromo-1, 2,3, 4-tetrahydroisoquinoline | 苏州艾缇克药物化学有限公司 | 2025-02-11 | — | — | CN | disclosed |
| US-20250011288-A1 | RXFP1 AGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2025-01-09 | — | — | US | disclosed |
| EP-4423068-A1 | RXFP1 AGONISTS | Bristol-Myers Squibb Company (US) | 2024-09-04 | — | — | EP | disclosed |
| CN-118510758-A | RXFP1 agonists | 百时美施贵宝公司 | 2024-08-16 | — | — | CN | disclosed |
| US-11952363-B2 | Piperazine compounds for the treatment of autoimmune disease | HOFFMANN-LA ROCHE INC. (US) | 2024-04-09 | — | — | US | disclosed |
| US-11746097-B2 | LXR inverse agonists for treatment of cancer | SAINT LOUIS UNIVERSITY (US) | 2023-09-05 | — | — | US | disclosed |
| US-20230192645-A1 | INDOLE CARBOXAMIDE COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2023-06-22 | — | — | US | disclosed |
| WO-2023077070-A1 | RXFP1 AGONISTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-05-04 | — | — | WO | disclosed |
| US-11623921-B2 | Indole carboxamide compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-04-11 | — | — | US | disclosed |
| US-6414154-B1 | TREATING PSYCHOTIC CONDITIONS OR SUBSTANCE ABUSE | SMITHKLINE BEECHAM P.L.C. (GB) | 2002-07-02 | — | — | US | disclosed |
| US-6274593-B1 | TREATING PSYCHOLOGICAL DISORDERS, SCHIZOPHRENIA, AND PARKINSON*S DISEASE | SMITHKLINE BEECHAM P.L.C. (GB) | 2001-08-14 | — | — | US | disclosed |
| EP-1086095-A1 | TETRAHYDROISOQUINOLINE DERIVATIVES AS MODULATORS OF DOPAMINE D3 RECEPTORS | SMITHKLINE BEECHAM PLC (GB) | 2001-03-28 | — | — | EP | disclosed |
| EP-1086084-A1 | TETRAISOQUINOLOLINE DERIVATIVES AS MODULATORS OF DOPAMINE D3 RECEPTORS | SMITHKLINE BEECHAM PLC (GB) | 2001-03-28 | — | — | EP | disclosed |
| EP-0983244-A1 | TETRAHYDROISOQUINOLINE DERIVATIVES AS MODULATORS OF DOPAMINE D3 RECEPTORS | SMITHKLINE BEECHAM PLC (GB) | 2000-03-08 | — | — | EP | disclosed |
| EP-0980357-A1 | SUBSTITUTED TETRAHYDRO ISOQUINOLINES AS MODULATORS OF DOPAMINE D3 RECEPTORS | SMITHKLINE BEECHAM PLC (GB) | 2000-02-23 | — | — | EP | disclosed |
| WO-1999064412-A1 | TETRAHYDROISOQUINOLINE DERIVATIVES AS MODULATORS OF DOPAMINE D3 RECEPTORS | SMITHKLINE BEECHAM P.L.C. (GB) | 1999-12-16 | — | — | WO | disclosed |
| WO-1999059974-A1 | TETRAISOQUINOLOLINE DERIVATIVES AS MODULATORS OF DOPAMINE D3 RECEPTORS | SMITHKLINE BEECHAM PLC (GB) | 1999-11-25 | — | — | WO | disclosed |
| WO-1998050363-A1 | SUBSTITUTED TETRAHYDRO ISOQUINOLINES AS MODULATORS OF DOPAMINE D3 RECEPTORS | SMITHKLINE BEECHAM PLC (GB) | 1998-11-12 | — | — | WO | disclosed |
| WO-1998050364-A1 | TETRAHYDROISOQUINOLINE DERIVATIVES AS MODULATORS OF DOPAMINE D3 RECEPTORS | SMITHKLINE BEECHAM PLC (GB) | 1998-11-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11746097-B2 | LXR inverse agonists for treatment of cancer | NR1H2, NR1H3, PPARD | DRD2 3734/4885DRD3 3293/4885MAOB 4501/4885 |
| US-20230192645-A1 | INDOLE CARBOXAMIDE COMPOUNDS | BTK, JAK2, BRD4 | DRD2 1489/4885DRD3 1253/4885MAOB 643/4885 |
| US-11952363-B2 | Piperazine compounds for the treatment of autoimmune disease | SSB, HLA-DRB1, IL5 | DRD2 1668/4885DRD3 1554/4885MAOB 3803/4885 |
| US-11623921-B2 | Indole carboxamide compounds | BTK, JAK2, BRD4 | DRD2 1489/4885DRD3 1253/4885MAOB 643/4885 |
| US-20250011288-A1 | RXFP1 AGONISTS | RXFP1, RXFP2, RXFP3 | DRD2 1890/4885DRD3 1853/4885MAOB 3104/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.